| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ethanol | 48 | 2024 | 306 | 6.610 |
Why?
|
| Liver Diseases, Alcoholic | 15 | 2024 | 85 | 4.110 |
Why?
|
| Monocytes | 33 | 2018 | 345 | 3.510 |
Why?
|
| Alcohol Drinking | 17 | 2025 | 288 | 2.610 |
Why?
|
| Liver | 21 | 2024 | 795 | 2.200 |
Why?
|
| Cytokines | 23 | 2024 | 915 | 2.170 |
Why?
|
| Toll-Like Receptor 4 | 15 | 2019 | 339 | 2.150 |
Why?
|
| Macrophages | 18 | 2020 | 1015 | 1.980 |
Why?
|
| Hepatitis, Alcoholic | 5 | 2024 | 77 | 1.820 |
Why?
|
| Inflammation | 22 | 2025 | 1099 | 1.680 |
Why?
|
| Alcoholism | 12 | 2022 | 310 | 1.600 |
Why?
|
| NF-kappa B | 16 | 2010 | 460 | 1.370 |
Why?
|
| Heat Shock Transcription Factors | 4 | 2022 | 12 | 1.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 24 | 2018 | 588 | 1.140 |
Why?
|
| Fatty Liver | 8 | 2020 | 98 | 1.110 |
Why?
|
| Fatty Liver, Alcoholic | 5 | 2014 | 33 | 1.040 |
Why?
|
| Benzoquinones | 3 | 2020 | 14 | 1.020 |
Why?
|
| Immunity, Innate | 8 | 2016 | 774 | 1.020 |
Why?
|
| Lactams, Macrocyclic | 3 | 2020 | 25 | 1.010 |
Why?
|
| Adipose Tissue | 3 | 2019 | 283 | 1.000 |
Why?
|
| HSP90 Heat-Shock Proteins | 3 | 2020 | 64 | 0.950 |
Why?
|
| Lipopolysaccharides | 23 | 2018 | 627 | 0.940 |
Why?
|
| Liver Diseases | 6 | 2020 | 137 | 0.940 |
Why?
|
| Dendritic Cells | 10 | 2008 | 515 | 0.940 |
Why?
|
| Myeloid Differentiation Factor 88 | 6 | 2018 | 205 | 0.880 |
Why?
|
| Animals | 50 | 2025 | 19650 | 0.870 |
Why?
|
| Signal Transduction | 14 | 2020 | 2903 | 0.820 |
Why?
|
| Hepatic Stellate Cells | 1 | 2022 | 23 | 0.780 |
Why?
|
| Actins | 3 | 2022 | 259 | 0.750 |
Why?
|
| DNA-Binding Proteins | 3 | 2014 | 1151 | 0.740 |
Why?
|
| Interleukin-10 | 10 | 2011 | 149 | 0.730 |
Why?
|
| Toll-Like Receptors | 9 | 2011 | 426 | 0.730 |
Why?
|
| Kupffer Cells | 6 | 2020 | 42 | 0.730 |
Why?
|
| Heat-Shock Response | 3 | 2022 | 35 | 0.670 |
Why?
|
| Transcription Factors | 6 | 2014 | 1471 | 0.670 |
Why?
|
| Memory Disorders | 1 | 2019 | 48 | 0.640 |
Why?
|
| Encephalitis | 1 | 2019 | 34 | 0.640 |
Why?
|
| Mice | 25 | 2022 | 10294 | 0.630 |
Why?
|
| Humans | 71 | 2025 | 59389 | 0.620 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2018 | 81 | 0.590 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2018 | 65 | 0.580 |
Why?
|
| Triglycerides | 3 | 2020 | 231 | 0.580 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2018 | 78 | 0.570 |
Why?
|
| Binge Drinking | 1 | 2018 | 27 | 0.570 |
Why?
|
| Liver Transplantation | 2 | 2021 | 207 | 0.560 |
Why?
|
| Heat-Shock Proteins | 3 | 2022 | 65 | 0.560 |
Why?
|
| Macrophage Activation | 3 | 2014 | 118 | 0.560 |
Why?
|
| Adipocytes | 1 | 2019 | 255 | 0.540 |
Why?
|
| Toll-Like Receptor 2 | 11 | 2008 | 219 | 0.530 |
Why?
|
| T-Lymphocytes | 6 | 2004 | 986 | 0.500 |
Why?
|
| Oxidative Stress | 8 | 2015 | 279 | 0.490 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 121 | 0.490 |
Why?
|
| Sex Characteristics | 2 | 2016 | 197 | 0.490 |
Why?
|
| Interleukin-6 | 10 | 2018 | 309 | 0.480 |
Why?
|
| RNA, Messenger | 11 | 2022 | 1466 | 0.480 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2015 | 6 | 0.480 |
Why?
|
| Mice, Inbred C57BL | 15 | 2019 | 3231 | 0.470 |
Why?
|
| Genes, Neoplasm | 1 | 2015 | 24 | 0.470 |
Why?
|
| Esophageal Achalasia | 1 | 2015 | 28 | 0.460 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2015 | 71 | 0.460 |
Why?
|
| Female | 44 | 2020 | 30724 | 0.450 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 98 | 0.440 |
Why?
|
| Chemokine CCL2 | 3 | 2011 | 54 | 0.440 |
Why?
|
| Immune Tolerance | 2 | 2014 | 172 | 0.440 |
Why?
|
| Lipogenesis | 1 | 2014 | 65 | 0.430 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2013 | 39 | 0.420 |
Why?
|
| Interleukin-12 | 6 | 2004 | 123 | 0.420 |
Why?
|
| Central Nervous System Depressants | 4 | 2010 | 42 | 0.420 |
Why?
|
| Fatty Acids | 1 | 2014 | 191 | 0.410 |
Why?
|
| Disease Models, Animal | 9 | 2020 | 2053 | 0.400 |
Why?
|
| Receptors, CCR2 | 1 | 2011 | 14 | 0.380 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 331 | 0.380 |
Why?
|
| DNA Damage | 1 | 2013 | 279 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2016 | 805 | 0.360 |
Why?
|
| Male | 31 | 2020 | 27747 | 0.360 |
Why?
|
| Immune System | 2 | 2008 | 129 | 0.340 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 2 | 2009 | 33 | 0.330 |
Why?
|
| Congresses as Topic | 4 | 2020 | 72 | 0.330 |
Why?
|
| Adult | 25 | 2020 | 15683 | 0.330 |
Why?
|
| Middle Aged | 24 | 2020 | 16314 | 0.330 |
Why?
|
| Lipopolysaccharide Receptors | 6 | 2008 | 143 | 0.330 |
Why?
|
| Endotoxins | 3 | 2016 | 78 | 0.300 |
Why?
|
| Isoantigens | 3 | 2004 | 71 | 0.300 |
Why?
|
| Neoplasms | 2 | 2017 | 1231 | 0.290 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 357 | 0.290 |
Why?
|
| Alcoholic Intoxication | 3 | 2015 | 27 | 0.290 |
Why?
|
| Transcription Factor RelA | 2 | 2007 | 50 | 0.290 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 48 | 0.280 |
Why?
|
| Mice, Knockout | 7 | 2022 | 1997 | 0.280 |
Why?
|
| Antigen-Presenting Cells | 2 | 2004 | 177 | 0.270 |
Why?
|
| Receptors, Cell Surface | 3 | 2005 | 428 | 0.270 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 178 | 0.270 |
Why?
|
| Hepatocytes | 4 | 2011 | 196 | 0.270 |
Why?
|
| Membrane Glycoproteins | 4 | 2005 | 661 | 0.260 |
Why?
|
| Interferon-alpha | 3 | 2008 | 99 | 0.260 |
Why?
|
| Gene Expression | 4 | 2019 | 809 | 0.260 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2006 | 32 | 0.260 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2002 | 27 | 0.250 |
Why?
|
| Interleukin-1beta | 2 | 2020 | 258 | 0.250 |
Why?
|
| Liver Cirrhosis | 2 | 2022 | 163 | 0.240 |
Why?
|
| Cell Line | 4 | 2018 | 1983 | 0.240 |
Why?
|
| Adolescent | 8 | 2018 | 5838 | 0.240 |
Why?
|
| Clonal Anergy | 1 | 2004 | 23 | 0.230 |
Why?
|
| Immunity | 1 | 2025 | 101 | 0.230 |
Why?
|
| Metabolic Diseases | 1 | 2024 | 54 | 0.220 |
Why?
|
| Reactive Oxygen Species | 3 | 2017 | 205 | 0.220 |
Why?
|
| Young Adult | 3 | 2020 | 4272 | 0.220 |
Why?
|
| I-kappa B Proteins | 2 | 2002 | 39 | 0.220 |
Why?
|
| Down-Regulation | 6 | 2012 | 306 | 0.210 |
Why?
|
| Immunosuppressive Agents | 2 | 2004 | 365 | 0.210 |
Why?
|
| In Vitro Techniques | 4 | 2020 | 472 | 0.210 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 62 | 0.200 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2002 | 66 | 0.200 |
Why?
|
| Viral Core Proteins | 3 | 2007 | 31 | 0.190 |
Why?
|
| Lymphocyte Activation | 3 | 2001 | 743 | 0.190 |
Why?
|
| Liver Cirrhosis, Alcoholic | 2 | 2020 | 19 | 0.190 |
Why?
|
| Tacrolimus | 1 | 2001 | 62 | 0.190 |
Why?
|
| Alanine Transaminase | 2 | 2019 | 38 | 0.190 |
Why?
|
| Cyclosporine | 1 | 2001 | 76 | 0.180 |
Why?
|
| Inflammation Mediators | 3 | 2014 | 171 | 0.180 |
Why?
|
| Hepacivirus | 4 | 2007 | 140 | 0.170 |
Why?
|
| Epigenetic Repression | 1 | 2020 | 3 | 0.170 |
Why?
|
| Interleukin-18 | 1 | 2020 | 71 | 0.170 |
Why?
|
| Interferon-gamma | 8 | 2008 | 551 | 0.170 |
Why?
|
| Caspase 1 | 1 | 2020 | 107 | 0.170 |
Why?
|
| CHO Cells | 5 | 2007 | 189 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2001 | 167 | 0.160 |
Why?
|
| Myeloid Cells | 4 | 2011 | 89 | 0.160 |
Why?
|
| Cricetinae | 5 | 2007 | 366 | 0.160 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 107 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 276 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 278 | 0.150 |
Why?
|
| Hepatitis C | 3 | 2005 | 143 | 0.150 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2018 | 2 | 0.150 |
Why?
|
| Chemokine CCL5 | 1 | 2018 | 32 | 0.150 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2020 | 250 | 0.150 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2018 | 12 | 0.150 |
Why?
|
| Poly I-C | 1 | 2018 | 76 | 0.150 |
Why?
|
| RAW 264.7 Cells | 1 | 2018 | 49 | 0.150 |
Why?
|
| Chemokine CXCL10 | 1 | 2018 | 56 | 0.140 |
Why?
|
| Hippocampus | 1 | 2019 | 246 | 0.140 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 171 | 0.140 |
Why?
|
| Interferon-beta | 1 | 2018 | 76 | 0.140 |
Why?
|
| Granuloma | 2 | 2008 | 41 | 0.140 |
Why?
|
| STAT3 Transcription Factor | 2 | 2008 | 67 | 0.140 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 679 | 0.140 |
Why?
|
| Phenotype | 3 | 2020 | 1137 | 0.140 |
Why?
|
| Interleukin-1 | 4 | 2006 | 157 | 0.140 |
Why?
|
| Cells, Cultured | 8 | 2011 | 2092 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 186 | 0.130 |
Why?
|
| Liver Function Tests | 2 | 2014 | 36 | 0.130 |
Why?
|
| Time Factors | 3 | 2016 | 3615 | 0.130 |
Why?
|
| NF-kappa B p50 Subunit | 2 | 2014 | 23 | 0.130 |
Why?
|
| Hepatitis C, Chronic | 2 | 2007 | 88 | 0.130 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 1206 | 0.130 |
Why?
|
| Choline Deficiency | 3 | 2011 | 14 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2018 | 256 | 0.120 |
Why?
|
| Lymphocyte Antigen 96 | 3 | 2011 | 47 | 0.120 |
Why?
|
| Methionine | 3 | 2011 | 53 | 0.120 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2008 | 64 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 309 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 221 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2017 | 228 | 0.120 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 2 | 2011 | 7 | 0.120 |
Why?
|
| Public Opinion | 1 | 2014 | 22 | 0.120 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 203 | 0.120 |
Why?
|
| Biomarkers | 3 | 2024 | 1307 | 0.110 |
Why?
|
| Blotting, Western | 4 | 2007 | 583 | 0.110 |
Why?
|
| PPAR alpha | 1 | 2014 | 29 | 0.110 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2014 | 22 | 0.110 |
Why?
|
| MicroRNAs | 2 | 2010 | 616 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 676 | 0.110 |
Why?
|
| Antigen Presentation | 3 | 2005 | 226 | 0.110 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2004 | 142 | 0.100 |
Why?
|
| Obesity | 2 | 2019 | 1166 | 0.100 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 203 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2006 | 238 | 0.100 |
Why?
|
| Aged | 3 | 2020 | 13406 | 0.100 |
Why?
|
| Acyl-CoA Oxidase | 1 | 2011 | 7 | 0.100 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2011 | 5 | 0.100 |
Why?
|
| Random Allocation | 1 | 2012 | 192 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 650 | 0.090 |
Why?
|
| Liver Cirrhosis, Experimental | 1 | 2011 | 4 | 0.090 |
Why?
|
| Lung | 4 | 2022 | 920 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 32 | 0.090 |
Why?
|
| RNA Interference | 1 | 2014 | 590 | 0.090 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2011 | 90 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2011 | 41 | 0.090 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2008 | 33 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 2 | 2009 | 203 | 0.090 |
Why?
|
| Cricetulus | 2 | 2007 | 99 | 0.080 |
Why?
|
| RNA Stability | 1 | 2010 | 97 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2010 | 717 | 0.080 |
Why?
|
| Binding Sites | 1 | 2012 | 881 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2007 | 127 | 0.080 |
Why?
|
| Receptors, Cytokine | 1 | 2009 | 13 | 0.080 |
Why?
|
| Interferon Type I | 1 | 2011 | 169 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1091 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 70 | 0.080 |
Why?
|
| Propionibacterium acnes | 2 | 2008 | 6 | 0.080 |
Why?
|
| Diet | 2 | 2009 | 497 | 0.080 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 14 | 0.080 |
Why?
|
| Probiotics | 1 | 2009 | 44 | 0.080 |
Why?
|
| STAT1 Transcription Factor | 1 | 2008 | 35 | 0.080 |
Why?
|
| Phosphorylation | 2 | 2007 | 883 | 0.070 |
Why?
|
| Protein Binding | 2 | 2002 | 1555 | 0.070 |
Why?
|
| Leptin | 2 | 2005 | 83 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 234 | 0.070 |
Why?
|
| Killer Cells, Natural | 1 | 2009 | 218 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 1368 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 51 | 0.070 |
Why?
|
| Pancreatitis, Alcoholic | 1 | 2007 | 3 | 0.070 |
Why?
|
| Cell Separation | 1 | 2008 | 145 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 4 | 2009 | 170 | 0.070 |
Why?
|
| Risk Factors | 1 | 2017 | 4986 | 0.070 |
Why?
|
| Alcohols | 1 | 2007 | 12 | 0.070 |
Why?
|
| Sp1 Transcription Factor | 1 | 2007 | 21 | 0.070 |
Why?
|
| Acute Disease | 1 | 2009 | 658 | 0.070 |
Why?
|
| Transcription Factor AP-1 | 1 | 2007 | 41 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 446 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2007 | 60 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 495 | 0.070 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2007 | 90 | 0.070 |
Why?
|
| Cyclic AMP | 2 | 1998 | 142 | 0.070 |
Why?
|
| Models, Biological | 2 | 2009 | 1143 | 0.070 |
Why?
|
| Heme Oxygenase-1 | 1 | 2006 | 18 | 0.070 |
Why?
|
| Cell Differentiation | 4 | 2004 | 1304 | 0.070 |
Why?
|
| Propionibacterium | 1 | 2005 | 5 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2003 | 206 | 0.060 |
Why?
|
| Membrane Microdomains | 1 | 2006 | 49 | 0.060 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2005 | 29 | 0.060 |
Why?
|
| Hepatitis | 1 | 2005 | 55 | 0.060 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 297 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 224 | 0.060 |
Why?
|
| RNA | 1 | 2008 | 401 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 202 | 0.060 |
Why?
|
| Antigens, Ly | 1 | 2004 | 42 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2006 | 146 | 0.060 |
Why?
|
| Cell Nucleus | 3 | 2007 | 608 | 0.060 |
Why?
|
| Cytoplasm | 2 | 2007 | 270 | 0.050 |
Why?
|
| Growth Inhibitors | 1 | 2003 | 25 | 0.050 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2002 | 26 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2003 | 164 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 63 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2002 | 35 | 0.050 |
Why?
|
| Macrophages, Alveolar | 1 | 2022 | 61 | 0.050 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2003 | 93 | 0.050 |
Why?
|
| Response Elements | 1 | 2002 | 43 | 0.050 |
Why?
|
| Jurkat Cells | 1 | 2002 | 104 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2001 | 37 | 0.050 |
Why?
|
| Ligands | 3 | 2007 | 411 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2002 | 201 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 450 | 0.040 |
Why?
|
| Cell Survival | 1 | 2002 | 559 | 0.040 |
Why?
|
| Lung Diseases | 2 | 2015 | 170 | 0.040 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2011 | 28 | 0.040 |
Why?
|
| Blood Donors | 1 | 1999 | 22 | 0.040 |
Why?
|
| Boston | 1 | 2020 | 247 | 0.040 |
Why?
|
| Colorado | 1 | 2018 | 19 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 1999 | 87 | 0.040 |
Why?
|
| Lymphocytes | 1 | 1998 | 190 | 0.040 |
Why?
|
| Escherichia coli | 2 | 1999 | 695 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2010 | 365 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 1996 | 206 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 1552 | 0.030 |
Why?
|
| Superantigens | 1 | 1995 | 10 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2007 | 205 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 527 | 0.030 |
Why?
|
| Psoriasis | 1 | 2015 | 50 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2008 | 1051 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2015 | 114 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3067 | 0.030 |
Why?
|
| Brain | 2 | 2015 | 1488 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2015 | 205 | 0.020 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2015 | 200 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 1994 | 229 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2011 | 16 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1119 | 0.020 |
Why?
|
| Asthma | 1 | 2015 | 460 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2011 | 63 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2011 | 67 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 53 | 0.020 |
Why?
|
| Collagen | 1 | 2011 | 115 | 0.020 |
Why?
|
| Cell Communication | 1 | 2011 | 124 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 221 | 0.020 |
Why?
|
| Apoptosis | 2 | 2006 | 1033 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2011 | 170 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2009 | 39 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 617 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2009 | 59 | 0.020 |
Why?
|
| Chimera | 1 | 2008 | 40 | 0.020 |
Why?
|
| NADP | 1 | 2008 | 22 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2008 | 5 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 1 | 2008 | 8 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 53 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2008 | 202 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 354 | 0.020 |
Why?
|
| Leukopenia | 1 | 2006 | 16 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2007 | 127 | 0.020 |
Why?
|
| Membrane Fluidity | 1 | 2006 | 14 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2006 | 99 | 0.020 |
Why?
|
| Receptors, Scavenger | 1 | 2005 | 9 | 0.020 |
Why?
|
| Liver Failure, Acute | 1 | 2005 | 16 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2006 | 359 | 0.020 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2005 | 8 | 0.020 |
Why?
|
| Listeriosis | 1 | 2005 | 29 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2005 | 13 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 137 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 45 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 347 | 0.020 |
Why?
|
| Cell Death | 1 | 2006 | 271 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2006 | 177 | 0.020 |
Why?
|
| Mice, Obese | 1 | 2005 | 80 | 0.020 |
Why?
|
| Burns | 1 | 2005 | 41 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2005 | 70 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2005 | 176 | 0.010 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2004 | 22 | 0.010 |
Why?
|
| Cholesterol | 1 | 2006 | 252 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 327 | 0.010 |
Why?
|
| DNA | 1 | 2008 | 805 | 0.010 |
Why?
|
| Cell Movement | 1 | 2005 | 428 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2005 | 411 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 2003 | 100 | 0.010 |
Why?
|
| Mitochondria | 1 | 2005 | 343 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 2001 | 32 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 2002 | 117 | 0.010 |
Why?
|
| Prognosis | 1 | 2006 | 1597 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 443 | 0.010 |
Why?
|
| B7-1 Antigen | 1 | 2001 | 73 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2001 | 182 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2006 | 2375 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2001 | 135 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2001 | 343 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2001 | 645 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1999 | 16 | 0.010 |
Why?
|
| Indomethacin | 1 | 1998 | 19 | 0.010 |
Why?
|
| Dinoprostone | 1 | 1998 | 44 | 0.010 |
Why?
|
| Chemokines | 1 | 1999 | 93 | 0.010 |
Why?
|
| Enterotoxins | 1 | 1996 | 20 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1994 | 148 | 0.010 |
Why?
|
| Sepsis | 1 | 1994 | 274 | 0.010 |
Why?
|